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ABSTACT 
 
Abdominal obesity (Ab-Ob) related to cardiometabolic risk, that is risk 
factor constellation for succeeded cardiovasculer disease and type 2 Diabetes 
Mellitus (DM). That factors such as atherogenic dislipidemia, hypertension, 
hyperglycemia, protrombotic state, and proinflammation state. Type 2 DM 
characterised by insulin resistance (IR). Plasma levels of retinol binding protein 4 
(RBP4) that is secreted by adipocytes are increased in insulin resistance (IR) state. 
Experiment in mice suggest that elevated RBP4 level cause IR. Although the 
underlying mechanism is not clearly understood, RBP4 considered play 
importance role consequently of type 2 DM in  Ab-Ob. 
This research was carried out to determine the role of high plasma RBP4 
level as a risk factor consequently of type 2 DM in Ab-Ob. The research was 
conducted by cross sectional analytic in 81 patients with Ab-Ob and case control 
study with matching on 33 patients with Ab-Ob type 2 DM as cases and 33 
patients with Ab-Ob non type 2 DM as control. The plasma of TNF-α, sTNFR1, 
and RBP4 levels was measured by ELISA. IR status of the patients was 
determined by HOMA-IR, whereas the β-cell function was determined by 
HOMA-B. Ab-Ob was defined by using criteria for Asian peoples (male WC ≥ 90 
cm; female WC ≥ 80 cm). The result of 81 patients with Ab-Ob showed that both 
plasma of TNF-α and sTNFR1 levels were significant positive correlated with 
plasma RBP4 level (coeficient correlation r = 0,294; p = 0,008 dan r = 0,458; p = 
<0,001 respectively). In addition, the plasma of RBP4 level significantly positive 
correlation with HOMA-IR (r = 0,450; p = 0,000) and significantly negative 
correlation with HOMA-B (r = -0,564; p = <0,001). In the matched case-control 
study, it was shown that mean plasma of RBP4 level of type 2 DM group (76,08 ± 
16,84 µg/ml) statistically higher than that without type 2 DM group (41,13 ± 
14,75 µg/ml) (p = <0,001). The odds ratio higher plasma of RBP4 level was 5,426 
(CI 95%; 1,343 – 21, 928) statistically significant for increases risk type 2 DM (p 
=  < 0,05). It has been proven that RBP4 was a dominant and consisten risk factor 
(66.9%, p = < 0.001) which influenced the incidence of type 2 DM in Ab-Ob. 
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It can be concluded that  high  plasma of RBP4 level have a greater risk to 
suffered from type 2 DM compared to low plasma of RBP4 in Ab-Ob. The high 
plasma of RBP4 level is most dominant and consistent risk factor consequently of 
type 2 DM.  These mechanism could behind the association between high plasma 
of RBP4 level and type 2 DM.  
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INTRODUCTION 
Abdominal obesity (Ab-Ob) is strongly related with the pathogenesis of IR 
and type 2 DM. Adipose tissue may be viewed as an endocrine organ that secreted 
many types of adipokines (such as free fatty acid, tumor necrosis factor-α, 
interleukin-6, and adiponectin) that modulate the action of insulin, protrombosis,  
and protrombosis.1,2,3 Moreover, RBP4, a new fat-derived adipokin that 
specifically binds to retinol, has recently been reported to provide a link between 
obesity and IR.4 RBP4 was discovered while trying to indentify the substance 
responsible for regulating insulin sensitivity in mice either lacking or 
overexpression GLUT4 in adipose tissue.5,6  It is regulated reciprocally in adipose 
tissue of mice overexpressing or lacking GLUT4. Circulating RBP4 level were 
reported to be raised in several different mouse models of obesity and IR.4 
Increasing the circulating levels of RBP4 leads to glucose intolerance, whereas 
knock out of the RBP4 gene increases insulin sensitivity.4 Study on human, serum 
RBP4 level correlated with magnitude of IR in subjects with obesity, impaired 
glucose tolerance, or type 2 DM, and in non obese, non diabetic subjects with 
strong family history of type 2 DM.7 Study in Ab-Ob patients have been reported 
thats plasma of RBP4 level correlated with RBP4 mRNA,8 and inflammation in 
adipose tissue.9  
Accordingly to the above findings, the pathobiological mechanism 
associated with the high plasma of RBP4 level in IR state and type 2 DM has not 
been studied. The plasma of RBP4 level is assumed to increase in Ab-Ob and 
linked to inflammation of adipose tissue and β-cell function. Therefore, it is 
importance to carry out a study to know high plasma of RBP4 level as risk factor 
type DM event in Ab-Ob. 
 
MATERIAL AND METHODS 
The study was conducted in two stages. First, a cross sectional analytic 
study was used to find out the relationship between plasma of TNF-α, soluble of 
tumor necrosis receptor (sTNFR)1 and  RBP4 level, and plasma of RBP4 level 
with β-cell function. The second stage, a matching case control study was 
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performed to know relationship between high plasma of RBP4 level with 
consequently of type 2 DM in Ab-Ob. The accessible population was all Ab-Ob 
patients who visited Sanjiwani Hospital.  The study subjects were patients with 
Ab-Ob (intended samples) selected from the accessible population that met the 
inclusion and exclusion by using consecutive sampling technique. The actual 
study subjects were patients with Ab-Ob who had confirmed to involve in this 
study by signing and informed consent. The criteria for Ab-Ob using the value 
waist circumference for men ≥ 90 cm and for women ≥ 80 cm. Exclusion criteria 
of study were: patients with coronarry heart disease, acute or chronic renal failure, 
acute or chronic liver malfunction, infection, malignancy, family hystori of type 2 
DM, taking drugs such as insulin, oral hypoglycemic, anti-inflammatory, anti- 
hypertensive, and hipolipidemia since at least  last two weeks and patient who did 
not consent to involve in the study. Patients who finally consent to joint the study 
were informed about the study aims.  
Blood samples were obtained from each subject after 8-hour overnight fast 
from an antecubital vein into Vacuteiner tubes. Fasting and 2 hours post prandial 
serum glucose, total cholesterol, trygliceride (TG), low-density lipoprotein (LDL)-
cholesterol, and high-density lipoprotein (HDL)-cholesterol levels were measured 
by enzymatic procedures using an autoanalyzer (Hitachi 912, Roche Diagnostic 
GmbH). Fasting insulin was measured by chemiluminescence immunoassay 
(Immulite 2000). Plasma sTNFR1, TNF-α , and RBP4 levels were measured by an 
enzym immunoassay kit (R&D Systems, Inc., Minneapolis, United State of 
America). IR was estimated by homeostasis model assessement of IR (HOMA-
IR).10  β-cell function was estimated by homeostasis model assessement of β-cell 
function (HOMA-B).11  
All collected data were first assessed before taken for analysis. The 
normality test of Kosmogorov-Smirnov was done to asses wether the data were 
normally distributed or not. Descriptive statistics was used to illustrate patients 
characteristics. Patient characteristics were compared among the two groups using 
one-way ANOVA. Pearson’s correlation coefficients were calculated to evaluate 
the relationship between plasma of RBP4 levels and several risk factors in this 
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study. Forward conditional logistic regression analyses was used to asses Odd’s 
Ratio (OR) between the high plasma of RBP4 level and consequently of type 2 
DM with control confounding variables (adjusted odd’s ratio). Path analyses 
models were also used to analyze the influence of risk factors that cause direct and 
indirect occurrence of type 2 DM. The above statistic analyses used p < 0.05 as 
the significance standard, by means of satistic software SPSS for windows version 
15.0. 
 
RESULTS 
A total 81 out of 104 of Ab-Ob patients were met the requirement as 
sample in this study, 37 were men (46%) and 44 were women (54%). Distribution 
of patient proportion suffering from type 2 DM was 40.7%, while dislipidemia 
and hypertension were 76.5% and 49.4% respectively. Most of the obtained data 
were not normally distributed by using Kosmogorov-Smirnov test at 5% 
significance level, except for height and blood HDL-cholesterol level. By using 
bivariate correlation, age, fasting blood sugar level, plasma of TNF-α , sTNFR1 
levels, and HOMA-IR were significantly positive correlated; whereas HOMA-B 
was significantly negative correlated with plasma of RBP4 level (Table 1). 
As many as 33 pairs of Ob-Ab patients with type 2 DM (as cases) and 
without type 2 DM (as control) from earlier cross-sectional study sample were 
used to determine the association between plasma of RBP4 level and type 2 DM. 
Selection for control group  was done by paired case based on age (Matching). 
From the data shown in Table 2, there are several variables were significantly 
different between case and control groups. There are several variables that 
potentially have confounding effects on the relationship between plasma RBP4 
level and type 2 DM status, which may affect the difference between case and 
control characteristics. It then analysed by using forward conditional logistic 
regression analysis to evaluate the association of RBP4 as a risk factor in type 2 
DM status. Table 3 represents regression analysis result that Ob-Ab patients with 
high plasma RBP4 level (≥ cuttoff) was likely 5.426 times to have type 2 DM 
compare to the patients who had plasma RBP4 under cuttoff (95% CI: 1.343 – 
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21.928). It implies that  high plasma of RBP4 levels increase the risk of type 2 
DM in the Ab-Ob patients. 
 
 
Table 1. Correlation between plasma of RBP4 level and various metabolic variables in Ab-Ob 
patients 
 
Variable  Plasma of RBP4 levels 
r p 
Age              0,240 0,031 
Waist circumference (cm)  0,053             0,637 
Blood pressure (mmHg): 
- systolic 
 
 
  0,045 0,692 
- diastolic        0,099 0,380 
Fasting blood glucose (mg/dl) 0,639 <0,001 
-    Cholesterol total (mg/dl)       0,180 0,109 
- HDL – cholesterol (mg/dl)       0,008 0,943 
- LDL – cholesterol (mg/dl)       0,172 0,124 
- Tryglicerid (mg/dl)       0,182 0,104 
Colesterol total/HDL ratio       0,125 0,265 
TNF- (pg/ml) 0,294 0,008 
sTNF R1 (ng/ml) 0,418 <0,001 
HOMA-IR 0,458 <0,001 
HOMA-B -0,564 <0,001 
 
 
In this research type 2 DM was dependent variable, while TNFα, sTNFR1, 
HOMA-IR, HOMA-B, and RBP4 were risk variables. However, only HOMA-IR 
directly influenced consequently of type 2 DM, whereas other variables 
influenced indirectly through other risk variables. The result of analysis model of 
risk factors for type 2 DM shows of RBP4 level was the most dominant and 
consistent risk factor (66.9%, p <0.001) on the consequently of type 2 DM in the 
patients with Ab-Ob. RBP4 concentration influenced both directly and indirectly 
through negative effects on HOMA-B and a positive on HOMA-IR (Figure 1).  
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Table 2. Characteristic between Ab-Ob patients with type 2 DM (as cases) and without type 2 DM 
(as control) 
 
Characteristics Cases 
 (n = 33) 
Control 
 (n = 33) 
p 
Age (year) 50,94  6,15 50,76  6,15   0,136 
Weight (kg) 88,44  13,10 87,44  12,24   0,789 
Height (cm) 159,98  7,77 160,98  6,80   0,592 
Waist circumferences (cm) 103,92  8,06 103,89  9,02   0,990 
Systolic BP (mmHg) 142,94  24,62 137,21  25,02   0,409 
Diastolic BP (mmHg) 83,12  11,65 78,96  13,73   0,236 
Hypertesion 51,52% 12,12% <0,001 
Fasting blood sugar (mg/dl) 197,76  59,04 96,33  9,63 <0,001 
2 hours PP blood sugar (mg/dl) 303,97  77,28 119,91  23,87 <0,001 
Total cholesterol (mg/dl) 221,61  35,911 212,64  39,65   0,273 
Hypercholesterolemia (mg/dl) 72,73% 54,55%   0,110 
HDL - cholesterol (mg/dl) 46,42  8,44 45,67  6,56   0,613 
HDL-hypocholesterolemia  33,33% 36,36%   0,768 
LDL - cholesterol (mg/dl) 146,24  33,38 132,73  28,56   0,071 
LDL-hypercholesterolemia 63,60% 54,50%   0,309 
Tryglicerid (mg/dl) 169,97  65,65 164,42  78,64   0,739 
Hypertrigliceridemia  57,58% 54,55%   0,786 
Total cholesterol / HDL ratio 6,53  8,63 4,73  1,05   0,247 
Insulin (µIU/ml) 7,85  3,59 7,69  5,13   0,877 
HOMA-IR 3,70  2,18 1,84  1,33 <0,001 
HOMA-B (%) 22,87  13,99 75,69  43,33 <0,001 
RBP4 (g/ml) 76,08  16,84 41,13  14,75 <0,001 
TNF- (pg/ml) 15,22  4,48 11,18  5,25   0,004 
sTNFR1 (ng/ml) 5,88  2,75 4,15  1,54   0,005 
 
 
Table 3. Multiple logistic regression analysis risk factors consequently of type 2 DM 
  
Variables  Adjusted OR CI 95% p 
1. Model 1 a. High HOMA-IR  6,923 (2,243 – 21,367) 0,001 
 b. Constant 0,070  0,001 
2. Model 2 a. High RBP4  5,858 (1,514 – 22,673) 0,010 
 b. High HOMA-IR  6,758 (2,042 – 22,370) 0,003 
 c. Constant 0,008  0,000 
3. Model 3 a. High RBP4  5,426 (1,343 – 21,928) 0,018 
 b. High HOMA-IR  5,129 (1,475 – 17,834) 0,010 
 c. High sTNFR1  3,712 (1,122 – 12,281) 0,032 
 d. Constant 0,002  0,000 
 8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Summary of the study 
 
 
 
DISCUSSION 
 
Tumor Necrosis Factor-α and Retinol Binding Protein 4 
TNF-α will activate adipokin expression change which involved in 
occurence of IR and type 2 DM in Ab-Ob patients through inflammatory 
signaling.7 The increase of RBP4 expression resulted from adiposa tissue and liver 
is influenced by TNF-α.9 We found a positive correlation between TNF-α 
concentration and plasma RBP4. Therefore, there is an indication that Ob-Ab is 
correlated with the increase of adipose tissue inflammatory response which is 
positively associated to the increased concentration of plasma RBP4. 
Concentration of RBP4 in blood circulation is influenced by the quantity 
of abdominal fat. When the abdominal fat is decreased, it  then leads to the 
decrease of RBP4 concentration.12,30 Other researchers have reported the 
HOMA-B 
HOMA-IR RBP4 
TYPE 2 DIABETES MELLITUS 
0.403 
-0.370 
0.298 
0.183 
0.182
-0.577 
0.308 
0.149 
-0.225 0.028 
0.413 
0.346 
ABDOMINAL OBESITY PATIENTS 
sTNFR1 TNF-α 
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concentration of circulating RBP4 was not associated with RBP4 expression in 
adipose tissue.13 This difference can be explained due to the different definition 
that were used in size criteria for Ab-Ob.  
 
Soluble Tumor Necrosis Factor Receptor 1, Retinol Binding Protein 4 and 
Insulin Resistance 
Examination of TNF-α system activity based on TNF-α receptor 
concentration will be more reliable, considering that this protein is easy to be 
recognized in the plasma and further, illustrate the degree of TNF- α system 
activity.14 sTNFR1 is a major mediator of TNF-α activity in the pathophysiology 
of IR and type 2 DM.15,16 Activation of MAP4K4 by TNF-α through TNFR1 
would reduce the expression of PPARγ and GLUT4 adiposit.17, 18 The decrease in 
GLUT4 expression would interfere the glucose transport in adipose tissue, which 
then stimulates the increased expression of RBP4.19 In this study, we found a 
significant positive correlation of sTNFR1 concentration with high plasma RBP4. 
The increase of RBP4 expression in Ab-Ob is correlated with the occurrence of RI 
in adipose tissue. The increase of this plasma RBP4 is then going to cause 
disruption in signaling skeletal muscle insulin and accompanied with stimulation 
of liver glucose production.9 In Ab-Ob patients, the high plasma RBP4 
concentration correlated with the degree of IR (measured by using the HOMA-
IR).  
Thus, it seems that there is a positive link between inflammation with the 
increased expression of RBP4, which is associated with the occurrence of IR. 
 
Retinol Binding Protein 4 and Beta Cell Secretion Function 
A significant negative correlation between high plasma RBP4 
concentration with beta cell secretion function in Ab-Ob patients was found in this 
study (measured by using the HOMA-B). This correlation can be the basic 
background for the association between the increased concentration of RBP4 and 
the incidence of type 2 DM. 
Pathophysiologically, retinol has correlation with beta cell function. RBP4 
circulation forms bond with transtiretin (TTR) protein, which is a functional 
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component of the increase of beta cell secretion.20 In the circulation, TTR binds 
strongly to RBP4. This can prevent TTR effect on beta cell secretion.21 Obtained 
data above implies that Ab-Ob patients could not adapt the low level of insulin 
sensitivity in the decreased insulin secretion.  
 
Retinol Binding Protein 4 and type 2 diabetes mellitus 
Plasma RBP4 concentration of type 2 DM was statistically higher than 
non-DM type 2 in this research. The high plasma of RBP4 level in type 2 DM 
may be related to the degree of obesity and RI.22 In this study, the Ab-Ob patients 
with high plasma of RBP4 level have 5 times greater risk to get type 2 diabetes 
mellitus compared to Ab-Ob patients with low plasma of RBP4 level (p = <0.05). 
First report was made in this study regarding high plasma RBP4 level as 
a risk factor for the incidence of Ab-Ob type 2 diabetes. There are several 
previous studies that reported a significant correlation of plasma levelof RBP4 
with the incidence of type 2 diabetes. However, these studies did not report how 
much of the RBP4 level influences the consequently of type 2 DM.23,24 
 
 
Risk Factors Effects on the Incidence of type 2 DM 
 Type 2 diabetes mellitus is a group of metabolic disorders are complex 
and heterogeneous. This type of DM resulted from IR and reduced secretion of 
cell beta combination.25     The failure of beta cell was caused by low concentration 
of adiponectin and high concentration of TNF-α. Indeed, these different 
concentrations are associated with the increase of diabetes risk, which is also 
related to insulin sensitivity and pancreatic function.26 In this study, plasma TNF-
α concentration could not be proven as a risk factor of the type 2 diabetes 
incidence.  This may be due to TNF-α is more active as autocrine / paracrine in 
the tissue. It is suspected that TNF-α endocrine effect is mediated by sTNFR1, 
which results in decreased expression of  PPARγ and GLUT4 adipose.23  The 
declined GLUT4 expression causes IR in adipocytes, and then stimulate the RBP4 
expression.4This process is likely occurred in Ab-Ob, where we got the level of 
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sTNFR1 plasma affected the incidence of type 2 diabetes indirectly through RBP4 
and HOMA-IR. 
RBP4 injection in normal mice will lead to IR, while the paralyzed rat 
have an increase of RBP4 in insulin sensitivity.4 This study proved that high 
plasma RBP4 level gives a positive influence on HOMA-IR. On the other hand, 
this protein was proved to give negative impact on HOMA-B. Thus, it seems that 
negative influence of RBP4 to HOMA-B is not associated with IR.27 IR state is an 
important risk factor for type 2 DM, although it is not the central pathological 
process of the disease. Beta cell dysfunction and apoptosis are important risk 
factors, which is likely that RBP4 correlated with IR and beta cell function.28,29 
This study has statistically and significantly proved that high plasma of RBP4 
level is the most dominant and consistent risk factor, which affects directly or 
indirectly the consequently of type 2 DM, through the HOMA-IR and HOMA-B. 
 
CONCLUSION 
In conclusion, high plasma of RBP4 level was significantly proven as a 
new risk factor type 2 DM. In accord with relationship between risk factor, plasma 
of RBP4 as a dominant and consistent risk factor influences consequently of type 
2 DM in the Ab-Ob.  
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